Bevacizumab (Avastin®), a full-length mAb against VEGFA, initially approved for the treatment of advanced carcinomas, has been used extensively also for age-related macular degeneration (AMD) and other chorioretinal vascular disorders [21,22]. Here, VEGFA is linked to age-related macular degeneration.